| Line 1: |
Line 1: |
| − | == Myeloproliferative Neoplasms (MPN) ==
| + | [[File:Dic(9 12).tif|300px]] |
| − | *[[Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive]]
| |
| − | *[[Chronic Neutrophilic Leukemia (CNL)]]
| |
| − | *[[Polycythemia Vera (PV)]]
| |
| − | *[[Primary Myelofibrosis (PMF)]]
| |
| − | *[[Essential Thrombocythemia (ET)]]
| |
| − | *[[Chronic Eosinophilic Leukemia, Not Otherwise Specified]]
| |
| − | *[[Myeloproliferative Neoplasm (MPN), Unclassifiable]]
| |
| | | | |
| − | == Mastocytosis == | + | ==Myeloproliferative Neoplasms (MPN)== |
| − | *[[Cutaneous Mastocytosis]] | + | *[[HAEM5:Chronic myeloid leukaemia]] |
| − | *[[Systemic Mastocytosis]] | + | *[[HAEM5:Chronic neutrophilic leukaemia]] |
| − | *[[Mast Cell Sarcoma]] | + | *[[HAEM5:Polycythaemia vera]] |
| | + | *[[HAEM5:Primary myelofibrosis]] |
| | + | *[[HAEM5:Chronic eosinophilic leukaemia]] |
| | + | *[[HAEM5:Myeloproliferative neoplasm, NOS]] |
| | + | *[[Some new stuff]] |
| | | | |
| − | == Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) ==
| |
| − | *[[Chronic Myelomonocytic Leukemia (CMML)]]
| |
| − | *[[Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative]]
| |
| − | *[[Juvenile Myelomonocytic Leukemia (JMML)]]
| |
| − | *[[Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)|MDS/MPN with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)]]
| |
| − | *[[Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable|MDS/MPN, Unclassifiable]]
| |
| | | | |
| − | == Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms ==
| + | '''Primary Author(s)*''' |
| − | *[[Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities|AML with Recurrent Genetic Abnormalities]] | |
| | | | |
| − | - [[Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1|AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1]]
| + | Put your text here |
| − | - [[Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11|AML with with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11]]
| |
| − | - [[Acute Promyelocytic Leukemia (APL) with PML-RARA]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3|AML with t(9;11)(p21.3;q23.3); KMT2A-MLLT3]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214|AML with t(6;9)(p23;q34.1); DEK-NUP214]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM|AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM]]
| |
| − | - [[Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1|AML Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with BCR-ABL1|AML with BCR-ABL1]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with Mutated NPM1|AML with Mutated NPM1]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA|AML with Biallelic Mutations of CEBPA]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with Mutated RUNX1|AML with Mutated RUNX1]]
| |
| | | | |
| − | *[[Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes|AML with Myelodysplasia-Related Changes]]
| |
| | | | |
| − | *[[Therapy-Related Myeloid Neoplasms]]
| + | '''Cancer Category/Type''' |
| | | | |
| − | *[[Acute Myeloid Leukemia (AML), Not Otherwise Specified|AML, Not Otherwise Specified]]
| + | Put your text here |
| | | | |
| − | - [[Acute Myeloid Leukemia (AML) with Minimal Differentiation|AML with Minimal Differentiation]]
| |
| − | - [[Acute Myeloid Leukemia (AML) without Maturation|AML without Maturation]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with Maturation|AML with Maturation]]
| |
| − | - [[Acute Myelomonocytic Leukemia]]
| |
| − | - [[Acute Monoblastic and Monocytic Leukemia]]
| |
| − | - [[Pure Erythroid Leukemia]]
| |
| − | - [[Acute Megakaryoblastic Leukemia (AMKL)]]
| |
| − | - [[Acute Basophilic Leukemia]]
| |
| − | - [[Acute Panmyelosis with Myelofibrosis]]
| |
| | | | |
| − | *[[Myeloid Sarcoma]]
| + | '''Cancer Sub-Classification/Subtype''' |
| | | | |
| − | *[[Myeloid Proliferations Associated with Down Syndrome]]
| + | Put your text here |
| | | | |
| − | - [[Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome]]
| |
| − | - [[Myeloid Leukemia Associated with Down Syndrome]]
| |
| | | | |
| − | *[[Blastic Plasmacytoid Dendritic Cell Neoplasm]]
| + | '''Definition/Description of Disease''' |
| | | | |
| − | *[[Acute Leukemias of Ambiguous Lineage]]
| + | Put your text here |
| | | | |
| − | - [[Acute Undifferentiated Leukemia]]
| |
| − | - [[Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1]]
| |
| − | - [[Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged]]
| |
| − | - [[Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified]]
| |
| − | - [[Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified]]
| |
| − | - [[Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types]]
| |
| − | - [[Acute Leukemias of Ambiguous Lineage, Not Otherwise Specified (NOS)]]
| |
| | | | |
| − | *[[Myeloid Neoplasms with Germline Predisposition]]
| + | '''Synonyms/Terminology''' |
| | | | |
| − | - [[Acute Myeloid Leukaemia with Germline CEBPA Mutation]]
| + | Put your text here |
| − | - [[Myeloid Neoplasms with Germline DDX41 Mutation]]
| |
| − | - [[Myeloid Neoplasms with Germline RUNX1 Mutation]]
| |
| − | - [[Myeloid Neoplasms with Germline ANKRD26 Mutation]]
| |
| − | - [[Myeloid Neoplasms with Germline ETV6 Mutation]]
| |
| − | - [[Myeloid Neoplasms with Germline GATA2 Mutation]]
| |
| | | | |
| − | == Myelodysplastic Syndromes (MDS) ==
| |
| − | *[[Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia|MDS with Single Lineage Dysplasia]]
| |
| − | *[[Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)|MDS with Ring Sideroblasts (MDS-RS)]]
| |
| − | *[[Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia|MDS with Ring Sideroblasts and Multilineage Dysplasia]]
| |
| − | *[[Myelodysplastic Syndrome (MDS) with Multilineage Dysplasia|MDS with Multilineage Dysplasia]]
| |
| − | *[[Myelodysplastic Syndrome (MDS) with Excess Blasts|MDS with Excess Blasts]]
| |
| − | *[[Myelodysplastic Syndrome (MDS) with Isolated del(5q)|MSD with Isolated del(5q)]]
| |
| − | *[[Myelodysplastic Syndrome (MDS), Unclassifiable|MDS, Unclassifiable]]
| |
| − | *[[Refractory Cytopenia of Childhood]]
| |
| | | | |
| − | == Precursor Lymphoid Neoplasms ==
| + | '''Epidemiology/Prevalence''' |
| − | *[[B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities]]
| |
| | | | |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1]]
| + | Put your text here |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with iAMP21]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified]]
| |
| | | | |
| − | *[[T-Lymphoblastic Leukemia/Lymphoma]]
| |
| | | | |
| − | - [[Early T-Cell Precursor Lymphoblastic Leukemia]]
| + | '''Clinical Features''' |
| − | - [[NK-Lymphoblastic Leukemia/Lymphoma]]
| |
| | | | |
| − | == Mature B-Cell Neoplasms == | + | Put your text here and fill in the table |
| − | *[[Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma]]
| + | <br /> |
| − | - [[Monoclonal B-cell Lymphocytosis]]
| + | {| class="wikitable" |
| | + | |'''Signs and Symptoms''' |
| | + | |EXAMPLE Asymptomatic (incidental finding on complete blood counts) |
| | | | |
| − | *[[B-cell Prolymphocytic Leukemia]]
| + | EXAMPLE B-symptoms (weight loss, fever, night sweats) |
| | | | |
| − | *[[Splenic Marginal Zone Lymphoma]]
| + | EXAMPLE Fatigue |
| | | | |
| − | *[[Hairy Cell Leukemia]]
| + | EXAMPLE Lymphadenopathy (uncommon) |
| | + | |- |
| | + | |'''Laboratory Findings''' |
| | + | |EXAMPLE Cytopenias |
| | | | |
| − | *[[Splenic B-cell Lymphoma/Leukemia, Unclassifiable]]
| + | EXAMPLE Lymphocytosis (low level) |
| − | - [[Splenic Diffuse Red Pulp Small B-cell Lymphoma]]
| + | |} |
| − | - [[Hairy Cell Leukemia Variant]]
| |
| | | | |
| − | *[[Lymphoplasmacytic Lymphoma]]
| |
| − | - [[Waldenstrom Macroglobulinemia]]
| |
| | | | |
| − | *[[IgM Monoclonal Gammopathy of Undetermined Significance]]
| + | '''Sites of Involvement''' |
| | | | |
| − | *[[Heavy Chain Diseases]]
| + | Put your text here |
| − | - [[Mu Heavy Chain Disease]]
| |
| − | - [[Gamma Heavy Chain Disease]]
| |
| − | - [[Alpha Heavy Chain Disease]]
| |
| | | | |
| − | *[[Plasma Cell Neoplasms]]
| |
| − | - [[Non-IgM Monoclonal Gammopathy of Undetermined Significance]]
| |
| − | - [[Plasma Cell Myeloma]]
| |
| − | - [[Plasma Cell Myeloma Variants]]
| |
| − | - [[Plasmacytoma]]
| |
| − | - [[Monoclonal Immunoglobulin Deposition Diseases]]
| |
| − | - [[Primary Amyloidosis]]
| |
| − | - [[Light Chain and Heavy Chain Deposition Disease]]
| |
| − | - [[Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome]]
| |
| − | - [[POEMS Syndrome]]
| |
| − | - [[TEMPI Syndrome]]
| |
| | | | |
| − | *[[Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)]]
| + | '''Morphologic Features''' |
| | | | |
| − | *[[Nodal Marginal Zone Lymphoma]]
| + | Put your text here |
| − | - [[Paediatric Nodal Marginal Zone Lymphoma]]
| |
| | | | |
| − | *[[Follicular Lymphoma]]
| |
| − | - [[Testicular Follicular Lymphoma]]
| |
| − | - [[In Situ Follicular Neoplasia]]
| |
| − | - [[Duodenal-Type Follicular Lymphoma]]
| |
| | | | |
| − | *[[Paediatric-Type Follicular Lymphoma]]
| + | '''Immunophenotype''' |
| | | | |
| − | *[[Large B-cell Lymphoma with IRF4 Rearrangement]]
| + | Put your text here and fill in the table |
| | + | <br /> |
| | + | {| class="wikitable" |
| | + | |'''Positive (universal)''' |
| | + | |EXAMPLE CD1 |
| | + | |- |
| | + | |'''Positive (subset)''' |
| | + | |EXAMPLE CD2 |
| | + | |- |
| | + | |'''Negative (universal)''' |
| | + | |EXAMPLE CD3 |
| | + | |- |
| | + | |'''Negative (subset)''' |
| | + | |EXAMPLE CD4 |
| | + | |} |
| | | | |
| − | *[[Primary Cutaneous Follicle Centre Lymphoma]]
| |
| | | | |
| − | *[[Mantle Cell Lymphoma]]
| + | '''Chromosomal Rearrangements (Gene Fusions)''' |
| − | - [[Leukemic Non-Nodal Mantle Cell Lymphoma]]
| |
| − | - [[In Situ Mantle Cell Neoplasia]]
| |
| | | | |
| − | *[[Diffuse Large B-cell Lymphoma, Not Otherwise Specified]]
| + | Put your text here and fill in the table |
| | + | <br /> |
| | + | {| class="wikitable" |
| | + | |'''Chromosomal Rearrangement''' |
| | + | |'''Genes in Fusion''' |
| | | | |
| − | *[[T-cell/Histiocyte-Rich Large B-cell Lymphoma]]
| + | '''(5’ or 3’ Segments)''' |
| | + | |'''Pathogenic Derivative''' |
| | + | |'''Prevalence''' |
| | + | |'''Diagnostic Significance (Yes, No or Unknown)''' |
| | + | |'''Prognostic Significance (Yes, No or Unknown)''' |
| | + | |'''Therapeutic Significance (Yes, No or Unknown)''' |
| | + | |'''Notes''' |
| | + | |- |
| | + | |EXAMPLE t(9;22)(q34;q11.2) |
| | + | |EXAMPLE 3'ABL1 / 5'BCR |
| | + | |EXAMPLE der(22) |
| | + | |EXAMPLE 20% (COSMIC) |
| | | | |
| − | *[[Primary Diffuse Large B-cell Lymphoma of the CNS]]
| + | EXAMPLE 30% (add reference) |
| | + | |Yes |
| | + | |No |
| | + | |Yes |
| | + | |EXAMPLE |
| | | | |
| − | *[[Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type]]
| + | The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |} |
| | | | |
| − | *[[EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)]]
| |
| | | | |
| − | *[[EBV-Positive Mucocutaneous Ulcer]]
| + | '''Individual Region Genomic Gain/Loss/LOH''' |
| | | | |
| − | *[[Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation]]
| + | Put your text here and fill in the table |
| − | - [[Fibrin-Associated Diffuse Large B-cell Lymphoma]]
| + | <br /> |
| | + | {| class="wikitable" |
| | + | |'''Chr #''' |
| | + | |'''Gain/Loss/Amp/LOH''' |
| | + | |'''Minimal Region Genomic Coordinates [Genome Build]''' |
| | + | |'''Minimal Region Cytoband''' |
| | + | |'''Diagnostic Significance (Yes, No or Unknown)''' |
| | + | |'''Prognostic Significance''' |
| | | | |
| − | *[[Lymphomatoid Granulomatosis]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Therapeutic Significance''' |
| | | | |
| − | *[[Primary Mediastinal (Thymic) Large B-cell Lymphoma]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Notes''' |
| | + | |- |
| | + | |EXAMPLE |
| | | | |
| − | *[[Intravascular Large B-cell Lymphoma]]
| + | 7 |
| | + | |EXAMPLE Loss |
| | + | |EXAMPLE |
| | | | |
| − | *[[ALK-Positive Large B-cell Lymphoma]]
| + | chr7:1- 159,335,973 [hg38] |
| | + | |EXAMPLE |
| | | | |
| − | *[[Plasmablastic Lymphoma]]
| + | chr7 |
| | + | |Yes |
| | + | |Yes |
| | + | |No |
| | + | |EXAMPLE |
| | | | |
| − | *[[Primary Effusion Lymphoma]]
| + | Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference). |
| | + | |- |
| | + | |EXAMPLE |
| | | | |
| − | *[[HHV8-Associated Lymphoproliferative Disorders]]
| + | 8 |
| − | - [[Multicentric Castleman Disease]]
| + | |EXAMPLE Gain |
| − | - [[HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)]]
| + | |EXAMPLE |
| − | - [[HHV8-Positive Germinotropic Lymphoproliferative Disorder]]
| |
| | | | |
| − | *[[Burkitt Lymphoma]]
| + | chr8:1-145,138,636 [hg38] |
| | + | |EXAMPLE |
| | | | |
| − | *[[Burkitt-Like Lymphoma with 11q Aberration]]
| + | chr8 |
| | + | |No |
| | + | |No |
| | + | |No |
| | + | |EXAMPLE |
| | | | |
| − | *[[High-Grade B-cell Lymphoma]]
| + | Common recurrent secondary finding for t(8;21) (add reference). |
| − | - [[High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements]]
| + | |- |
| − | - [[High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)]]
| + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |} |
| | | | |
| − | *[[B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma]]
| + | '''Characteristic Chromosomal Patterns''' |
| | | | |
| − | == Mature T- and NK-cell Neoplasms ==
| + | Put your text here |
| − | *[[T-cell Prolymphocytic Leukemia]]
| |
| | | | |
| − | *[[T-cell Large Granular Lymphocytic Leukemia]]
| + | {| class="wikitable" |
| | + | |'''Chromosomal Pattern''' |
| | + | |'''Diagnostic Significance (Yes, No or Unknown)''' |
| | + | |'''Prognostic Significance''' |
| | | | |
| − | *[[Chronic Lymphoproliferative Disorder of NK Cells]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Therapeutic Significance''' |
| | | | |
| − | *[[Aggressive NK-cell Leukemia]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Notes''' |
| | + | |- |
| | + | |EXAMPLE |
| | | | |
| − | *[[EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood]]
| + | Co-deletion of 1p and 18q |
| − | - [[Systemic EBV-Positive T-cell Lymphoma of Childhood]]
| + | |Yes |
| − | - [[Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form]]
| + | |No |
| − | - [[Hydroa Vacciniforme-Like Lymphoproliferative Disorder]]
| + | |No |
| − | - [[Severe Mosquito Bite Allergy]]
| + | |EXAMPLE: |
| | | | |
| − | *[[Adult T-cell Leukemia/Lymphoma]]
| + | See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |} |
| | | | |
| − | *[[Extranodal NK/T-cell Lymphoma, Nasal Type]]
| |
| | | | |
| − | *[[Intestinal T-cell Lymphoma]]
| + | '''Gene Mutations (SNV/INDEL)''' |
| − | - [[Enteropathy-Associated T-cell Lymphoma]]
| |
| − | - [[Monomorphic Epitheliotropic Intestinal T-cell Lymphoma]]
| |
| − | - [[Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)]]
| |
| − | - [[Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract]]
| |
| | | | |
| − | *[[Hepatosplenic T-cell Lymphoma]]
| + | Put your text here and fill in the table |
| | + | {| class="wikitable" |
| | + | |'''Gene; Genetic Alteration''' |
| | + | |'''Presumed Mechanism (Tumor Suppressor Gene (TSG)/Oncogene/Other)''' |
| | + | |'''Prevalence (COSMIC/ TCGA/Other)''' |
| | + | |'''Concomitant Mutations''' |
| | + | |'''Mutually Exclusive Mutations''' |
| | + | |'''Diagnostic Significance (Yes, No or Unknown)''' |
| | + | |'''Prognostic Significance''' |
| | | | |
| − | *[[Subcutaneous Panniculitis-Like T-cell Lymphoma]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Therapeutic Significance''' |
| | | | |
| − | *[[Mycosis Fungoides]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Notes''' |
| | + | |- |
| | + | |EXAMPLE: TP53; Variable LOF mutations |
| | | | |
| − | *[[Sézary Syndrome]]
| + | EXAMPLE: |
| | | | |
| − | *[[Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders]]
| + | EGFR; Exon 20 mutations |
| − | - [[Lymphomatoid Papulosis]]
| |
| − | - [[Primary Cutaneous Anaplastic Large Cell Lymphoma]]
| |
| | | | |
| − | *[[Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes]]
| + | EXAMPLE: BRAF; Activating mutations |
| − | - [[Primary Cutaneous Gamma Delta T-cell Lymphoma]]
| + | |EXAMPLE: TSG |
| − | - [[Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma]]
| + | |EXAMPLE: 20% (COSMIC) |
| − | - [[Primary Cutaneous Acral CD8+ T-cell Lymphoma]]
| |
| − | - [[Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder]]
| |
| | | | |
| − | *[[Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)]]
| + | EXAMPLE: 30% (add Reference) |
| | + | |EXAMPLE: IDH1 R123H |
| | + | |EXAMPLE: EGFR amplification |
| | + | | |
| | + | | |
| | + | | |
| | + | |EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference). |
| | + | <br /> |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |} |
| | + | Note: A more extensive list of mutations can be found in cBioportal (<nowiki>https://www.cbioportal.org/</nowiki>), COSMIC (<nowiki>https://cancer.sanger.ac.uk/cosmic</nowiki>), ICGC (<nowiki>https://dcc.icgc.org/</nowiki>) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. |
| | | | |
| − | *[[Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]]
| |
| − | - [[Angioimmunoblastic T-cell Lymphoma]]
| |
| − | - [[Follicular T-cell Lymphoma]]
| |
| − | - [[Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype]]
| |
| | | | |
| − | *[[Anaplastic Large Cell Lymphoma, ALK-Positive]]
| + | '''Epigenomic Alterations''' |
| | | | |
| − | *[[Anaplastic Large Cell Lymphoma, ALK-Negative]]
| + | Put your text here |
| | | | |
| − | *[[Breast Implant-Associated Anaplastic Large Cell Lymphoma]]
| + | '''Genes and Main Pathways Involved''' |
| | | | |
| | + | Put your text here and fill in the table |
| | + | {| class="wikitable" |
| | + | |'''Gene; Genetic Alteration''' |
| | + | |'''Pathway''' |
| | + | |'''Pathophysiologic Outcome''' |
| | + | |- |
| | + | |EXAMPLE: BRAF and MAP2K1; Activating mutations |
| | | | |
| − | <comments /> | + | EXAMPLE: CDKN2A; Inactivating mutations |
| | + | |
| | + | EXAMPLE: KMT2C and ARID1A; Inactivating mutations |
| | + | |EXAMPLE: MAPK signaling |
| | + | |
| | + | EXAMPLE: Cell cycle regulation |
| | + | |
| | + | EXAMPLE: Histone modification, chromatin remodeling |
| | + | |EXAMPLE: Increased cell growth and proliferation |
| | + | |
| | + | EXAMPLE: Unregulated cell division |
| | + | |
| | + | EXAMPLE: Abnormal gene expression program |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | |} |
| | + | |
| | + | |
| | + | '''Genetic Diagnostic Testing Methods''' |
| | + | |
| | + | Put your text here |
| | + | |
| | + | |
| | + | '''Familial Forms''' |
| | + | |
| | + | Put your text here |
| | + | |
| | + | |
| | + | '''Additional Information''' |
| | + | |
| | + | Put your text here |
| | + | |
| | + | |
| | + | '''Links''' |
| | + | |
| | + | Put your text placeholder here (use "Link" icon at top of page) |
| | + | |
| | + | |
| | + | '''References''' |
| | + | |
| | + | (use "Cite" icon at top of page) |
| | + | |
| | + | |
| | + | BOOK EXAMPLE: Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p130-149. |
| | + | |
| | + | '''Notes''' |
| | + | |
| | + | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. |